Several House Energy & Commerce health subcommittee members criticized CMS for setting up a biosimilar pay policy that treats the products as if they were interchangeable, but FDA and CMS officials said Thursday (Feb. 4) it is wrong to compare FDA approval criteria with Medicare payment policies. Many lawmakers have been ringing the alarm over rising drug prices, and CMS’ biosimilar payment policy aims to curb prices of biologics, which are among the most expensive therapies, yet not a single...